Shanghai Cryowise Medical Technology Co., Ltd.

Phase I: Primary Objective: To evaluate the safety and tolerability of HCL001 cell injection in patients with decompensated cirrhosis and determine the recommended phase 2 dose (RP2D). Secondary Objective: To evaluate the preliminary efficacy of HCL001 cell injection in patients with decompensated cirrhosis. Phase II: Primary Objective: To evaluate the preliminary efficacy of HCL001 cell injection in patients with decompensated cirrhosis. Secondary Objective: To evaluate the safety of HCL001 cell injection in patients with decompensated cirrhosis. Phase I/II: Exploratory Objective: To investigate the effects of HCL001 cell injection on liver histological changes, liver condition improvement (MRI, ultrasound, transient elastography of the liver and spleen), aspartate aminotransferase to platelet ratio index (APRI), four liver fibrosis indicators, endoscopic varicose vein severity, humoral immune function, T lymphocyte typing, changes in inflammatory factors, as well as PK, PD, and immunogenicity in patients with decompensated cirrhosis.